home

How Three Companies Have Been Resurrected from Failed Clinical Trials: George Zavoico of JonesTrading RVX, SNSS, THLD, AST, ABEO

Commentsthelifesciencesreport2016-04-08 17:17 Read   90

Data can create or destroy the value of a biotech investment in an instant, but hitting or missing an endpoint doesn't always tell the story.

FDA allows marketing of first-of-kind tissue containment system for use with certain laparoscopic power morcellators in select patients

RegulatorFDA 2016-04-08 12:35 Read   113

 The U.S. Food and Drug Administration today permitted the marketing of PneumoLiner, the first tissue containment system for use with certain laparoscopic power morcellators to isolate uterine tissue that is not suspected to contain cancer. Although the device is an effective tissue containment system, the FDA is requiring the manufacturer to warn patients and health care providers that PneumoLiner has not been proven to reduce the risk of spreading cancer during these procedures.

Amgen’s Response to Technology Assessments for Kyprolis® (Carfilzomib) in Multiple Myeloma

EVENTSAmgen2016-04-07 14:23 Read   127

At the same time as the pace of innovation in the fight against cancer has increased, so has the use of “technology assessments” to understand the economic value of innovation.

AstraZeneca and Takeda DPP-4 inhibitors get another warning added to their labels

RegulatorFierce pharma 2016-04-07 14:15 Read   121

There is more bad news for DPP-4 inhibitor diabetes drugs saxagliptin and alogliptin from AstraZeneca ($AZN) and Takeda. The FDA has tightened its regulatory grip on the Type 2 diabetes meds, insisting their labels now include warnings of increased risks of heart failure.

Early childhood antibiotics increase risk for prediabetes in adolescence

Healthhealio2016-04-07 14:02 Read   161

Young children who take antibiotics are more likely to develop prediabetes as adolescents, likely due to a decrease of beneficial microbiota in the gut, according to study findings presented here.

Allergan, Pfizer Cancel $160B Merger, Citing U.S. Treasury Actions

EVENTSXconomy2016-04-07 13:52 Read   94

Xconomy New York — The speculation turned out to be true: Pfizer and Allergan announced today that they are canceling a proposed $160 billion merger, in large part due to steps the U.S. Treasury Department is planning to prevent tax avoidance.

Picking winners still possible in Q1

EVENTSEP vantage2016-04-07 13:38 Read   106

Even in down markets there are wins to be had. Most mid and small-cap biopharma companies were in the red in the first quarter of 2016, but some groups were able to steer towards share price rises against the prevailing headwinds that left their bigger counterparts struggling to eke out any gains.

Health Tip: Is Your Child Ready for Potty Training?

Healthdrugs2016-04-07 13:13 Read   106

There are many factors to think about when it's time to consider toilet training a child.

J&J grabs prostate cancer rights for Tesaro's niraparib in $500M deal

R&DFiercebiotech2016-04-07 13:04 Read   87

Oncology powerhouse J&J ($JNJ) has stepped up with a $500 million deal to nab the commercial rights to Tesaro's ($TSRO) late-stage cancer drug niraparib, specifically carving out ownership of the drug for its growing prostate cancer franchise.

M Pharmaceutical Inc revives anti-obesity drug deal

EVENTSproactiveinvestors2016-04-07 12:53 Read   89

“This product fits into our mission of developing innovative technologies for obesity with fewer side effects than currently available products," said CEo Brian Keane.

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders

R&DPR newswire2016-04-07 11:27 Read   112

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited and Heptares have entered into a definitive agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer's disease.

Valeant moves quickly to slash jobs, beginning with Addyi, dermatology sales reps

R&Dfircepharma2016-04-06 13:01 Read   125

Last month, when outlining dismal sales performances in several of Valeant's ($VRX) key businesses, CEO J. Michael Pearson promised a restructuring.